Sennosides Market Size, Share, and Industry Analysis, By Dosage Form (Tablets, Liquid, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2025-2032

The global sennosides market is witnessing significant growth owing to the increasing prevalence of constipation among the general population, resulting in a rising focus of the key players toward R&D activities to launch novel products in the market. Sennosides refer to the medications, which are made up of senna, a laxative of plant origin that contains the anthraquinone glucosides sennoside A and sennoside B, used to treat constipation.

• According to 2023 statistics published by the National Center for Biotechnology Information (NCBI), the prevalence of constipation in older adults is 18.9%.

Sennosides Market Driver

Increasing Prevalence of Constipation to Drive Market Growth

The increasing prevalence of constipation, especially among key demographic groups such as pregnant women, is resulting in a rising demand for drugs to relieve constipation among the patients. This, along with the growing number of key players operating in the market, is focusing on the development and introduction of these products in the market.

• According to the 2024 statistics, the prevalence of constipation throughout pregnancy is 32.4%.

Download Free sample to learn more about this report.

According to statistics published by the Organisation for Economic Co-operation and Development (OECD), the R&D expenditure was USD 92.20 billion in the U.S., USD 12.70 billion in Japan, USD 21.20 billion in Europe, and USD 2.80 billion in other countries.

Sennosides Market Restraint

Limited Awareness in Emerging Countries to Hinder Market Growth

There is a growing demand for novel products for the treatment of constipation among the general population. However, limited awareness about the benefits of nutraceutical products such as sennosides among the general population is hampering the growth of the market globally.

• According to 2021 statistics published by the National Centers for Biotechnology Information (NCBI), it was reported that only 6.35% of women consume supplements in Brazil.

Sennosides Market Opportunity

Growing Preference for Herbal Supplements to Provide Future Market Growth Opportunities

There is a growing preference toward herbal supplements owing to the benefits such as fewer side effects, improved health, among others, resulting in the rising adoption rate for these products, such as sennosides, in the market. Increasing demand is shifting the focus of key players toward the development and introduction of these products in the market.

• According to 2024 data published by the Icahn School of Medicine at Mount Sinai, it was estimated that 80% of people rely on herbal medicines for some part of their primary health care globally.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Disorders, By Key Countries, 2023
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market

Analysis by Dosage Form

By dosage form, the market is segmented into tablets, liquid, and others.

The tablets segment held a prominent market share in 2023. The growing benefits of tablets, such as high physiological and chemical stability, ease of administration, among others, are resulting in a rising focus of major players towards R&D activities to launch sennosides, which is further expected to support the segmental growth.

• According to a 2024 study published by Dove Medical Press, it was reported that about 42.4% of respondents preferred tablets amongst the 300 respondents in Ethiopia.

Analysis by Distribution Channel

In terms of the distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment accounted for a substantial proportion of the market in 2023. The growth is due to the increasing number of retail pharmacies, further supporting the growing adoption rate for sennosides globally.

• According to 2021 data published by Commonwealth Fund, there are about 60,000 retail pharmacies in the U.S. Thus, the growing number of retail pharmacies is expected to drive the adoption rate for sennosides in the market.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global sennosides market in 2023. The growth is due to several factors, including the growing prevalence of constipation, increasing per capita healthcare expenditure, increasing acquisitions and mergers, among others.

• According to 2024 statistics published by the Centers for Medicare & Medicaid Services, it was reported that the per capita healthcare expenditure is USD 4.9 trillion in the U.S.

Additionally, Europe is the second-largest market for sennosides. The rising geriatric population is resulting in the growing prevalence of constipation, which is further contributing to the demand for novel sennosides products in the market. This, along with the growing focus of key players toward R&D activities to launch novel sennosides products, is likely to support the growth of the market.

• According to 2024 statistics published by NHS Inform, it was reported that around one in every seven adults has constipation at one time in the U.K.

On the other hand, Asia Pacific is also expected to grow at a considerable CAGR during the forecast period. The growth is due to the growing number of prominent players operating in the market offering innovative sennosides products in the market.

Key Players Covered

The global sennosides market is semi-consolidated, with few players operating in the global sennosides market. The report includes the profiles of the following key players:

• Globela Pharma Pvt. Ltd. (India)
• Avrio Health L.P. (U.S.)
• Manx Healthcare (U.K.)
• Abdi İbrahim İlaç Sanayii ve Tic. A.Ş. (Turkey)
• Patel Phyto Extractions Pvt. Ltd. (India)
• Atlantis Consumer Healthcare Inc. (U.S.)
• Himalaya Wellness Company (India)

Key Industry Developments

• In July 2021, Manx Healthcare launched a senna-based product, Cenlax 7.5mg tablets 12 Years Plus, with an aim to support patients suffering from constipation globally.
• In June 2021, Abdi İbrahim İlaç Sanayii ve Tic. A.Ş. acquired a 90% stake in INOLIVA, a player operating in the Turkish health sector, with an aim to support the launch of innovative products in the market.